Functional SGLT2 expression has been demonstrated in pancreatic and prostate carcinoma, while inhibition of SGLT2 by canagliflozin blocks glucose uptake to reduce tumor growth and improve survival in a xenograft model of pancreatic cancer [24]. This evidence concerns the gene SLC5A2 and pancreatic neoplasm.